Perspective Therapeutics’ (CATX) “Buy” Rating Reiterated at B. Riley

Perspective Therapeutics (NYSE:CATX)‘s stock had its “buy” rating restated by research analysts at B. Riley in a research note issued to investors on Monday, MarketBeat Ratings reports. They currently have a $12.00 price target on the stock, up from their previous price target of $9.00. B. Riley’s price target would indicate a potential upside of 214.96% from the stock’s current price. B. Riley also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Other equities research analysts have also recently issued reports about the stock. Truist Financial decreased their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Royal Bank Of Canada raised Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and lifted their price objective for the company from $15.00 to $16.00 in a research note on Tuesday, June 3rd. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Monday. Finally, Scotiabank started coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.56.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $3.81 on Monday. The firm’s 50-day moving average is $2.75 and its two-hundred day moving average is $2.85. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $16.55.

Insider Buying and Selling

In other news, Director Robert F. Williamson III purchased 38,145 shares of the stock in a transaction dated Monday, March 31st. The stock was acquired at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the acquisition, the director now owns 108,982 shares of the company’s stock, valued at $233,221.48. The trade was a 53.85% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Juan Graham acquired 33,333 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the purchase, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at $79,546.50. The trade was a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders bought 115,696 shares of company stock worth $256,344. Corporate insiders own 3.72% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently modified their holdings of the business. Affinity Asset Advisors LLC lifted its holdings in Perspective Therapeutics by 71.1% in the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock worth $4,738,000 after acquiring an additional 924,196 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of Perspective Therapeutics by 40.9% during the first quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock valued at $67,000 after purchasing an additional 9,082 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Perspective Therapeutics by 13.2% during the 1st quarter. HighTower Advisors LLC now owns 201,586 shares of the company’s stock worth $429,000 after purchasing an additional 23,475 shares during the period. Nuveen LLC bought a new stake in shares of Perspective Therapeutics in the 1st quarter worth approximately $2,647,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Perspective Therapeutics by 6.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company’s stock valued at $925,000 after purchasing an additional 27,119 shares during the period. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.